© The Author 2006. Published by Oxford University Press.
ARTICLE |
Ornithine Decarboxylase Polymorphism Modification of Response to Aspirin Treatment for Colorectal Adenoma Prevention
Affiliations of authors: Departments of Community and Family Medicine (ELRB, JAB, MVG) and Medicine (JAB), Dartmouth Medical School, Lebanon, NH; Lankenau Institute for Medical Research, Wynnewood, PA (SB, TGO); Department of Gastroenterology, Cleveland Clinic Foundation, Cleveland, OH (CAB); Department of Medicine, Division of Gastroenterology and Hepatology, University of North Carolina, Chapel Hill, NC (RSS); Department of Medicine, University of Colorado Health Sciences Center, Denver, CO (DJA); Department of Preventive Medicine, University of Southern California, Los Angeles, CA (RWH)
Correspondence to: Elizabeth L. R. Barry, PhD, Department of Community and Family Medicine, Dartmouth Medical School, 46 Centerra Parkway, Ste. 300, Lebanon, NH 03766 (e-mail: elizabeth.l.barry{at}dartmouth.edu).
Background: Previous research suggests that the G315A single-nucleotide polymorphism in the ornithine decarboxylase (ODC) gene may be a genetic marker for risk of colorectal neoplasia and may also modify the association of aspirin use with risk. Methods: We tested these hypotheses among participants in the Aspirin/Folate Polyp Prevention Study who were randomly assigned to placebo or to aspirin treatment (81 or 325 mg daily) and followed for 3 years for the occurrence of new adenomas. Genomic DNA from 973 subjects was analyzed for ODC genotype. Relative risks (RRs) and 95% confidence intervals (CIs) were calculated to test the association between ODC genotype and adenoma occurrence and interactions with aspirin treatment. All statistical tests were two-sided. Results: Of the 973 subjects, 54% were homozygous wild-type (GG), 7% were homozygous variant (AA), and 39% were heterozygous individuals; the allele frequencies varied statistically significantly by race and ethnicity. Among these subjects, the absolute risk of any adenoma was 45% and the risk of an advanced lesion was 10%. Overall, no association was found between ODC genotype and the occurrence of new adenomas, but genotype did modify the effect of aspirin on adenoma risk. Although aspirin treatment had no protective effect among subjects with a GG genotype, among subjects with at least one A allele, it was associated with statistically significant reduced risks of any adenoma (RR = 0.77, 95% CI = 0.63 to 0.95; P = .02, Pinteraction = .04) and of advanced lesions (RR = 0.51, 95% CI = 0.29 to 0.90; P = .02, Pinteraction = .02). Among subjects with at least one A allele, 40.8% who took aspirin versus 52.9% who took placbo developed adenomas; 7.1% versus 14.0% developed advanced lesions. Conclusion: ODC genotype may modify the response to aspirin treatment for colorectal adenoma prevention.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. A. Hubner, K. R. Muir, J.-F. Liu, R. F.A. Logan, M. J. Grainge, R. S. Houlston, and Members of the UKCAP Consortium Ornithine Decarboxylase G316A Genotype Is Prognostic for Colorectal Adenoma Recurrence and Predicts Efficacy of Aspirin Chemoprevention Clin. Cancer Res., April 15, 2008; 14(8): 2303 - 2309. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. Simoneau, E. W. Gerner, R. Nagle, A. Ziogas, S. Fujikawa-Brooks, H. Yerushalmi, T. E. Ahlering, R. Lieberman, C. E. McLaren, H. Anton-Culver, et al. The Effect of Difluoromethylornithine on Decreasing Prostate Size and Polyamines in Men: Results of a Year-Long Phase IIb Randomized Placebo-Controlled Chemoprevention Trial Cancer Epidemiol. Biomarkers Prev., February 1, 2008; 17(2): 292 - 299. [Abstract] [Full Text] [PDF]
|
|